Extracts from two ubiquitous Mediterranean plants ameliorate cellular and animal models of neurodegenerative proteinopathies

• Published in: Neuroscience Letters
• Main Authors: Briffa, Michelle, Ghio, Stephanie, Neuner, Johanna, Gauci, Alison J., Cacciottolo, Rebecca, Marchal, Christelle, Cullin, Christophe, Vassallo, Neville, Cauchi, Ruben J., Caruana Grech Perry, Mario
• Format: Article in Journal/Newspaper
• Language: English
• Published: Elsevier Ireland Ltd. 2016
• Subjects: Amyloid beta-protein; Organisms; Nervous system > Degeneration; Opuntia ficus-indica; Arctic
• Online Access: https://www.um.edu.mt/library/oar/handle/123456789/90343; https://doi.org/10.1016/j.neulet.2016.11.058

A signature feature of age-related neurodegenerative proteinopathies is the misfolding and aggregation of proteins, typically amyloid-B (AB) in Alzheimer’s disease (AD) and a-synuclein (a-syn) in Parkinson’s disease (PD), into soluble oligomeric structures that are highly neurotoxic. Cellular and animal models that faithfully replicate the hallmark features of these disorders are being increasing exploited to identify disease-modifying compounds. Natural compounds have been identified as a useful source of bioactive molecules with promising neuroprotective capabilities. In the present report, we investigated whether extracts derived from two ubiquitous Mediterranean plants namely, the prickly pear Opuntia ficusindica (EOFI) and the brown alga Padina pavonica (EPP) alleviate neurodegenerative phenotypes in yeast (Saccharomyces cerevisiae) and fly (Drosophila melanogaster) models of AD and PD. Pre-treatment with EPP or EOFI in the culture medium significantly improved the viability of yeast expressing the Arctic AB42 (E22G) mutant. Supplementing food with EOFI or EPP dramatically ameliorated lifespan and behavioural signs of flies with brain-specific expression of wild-type AB42 (model of late-onset AD) or the Arctic AB42 variant (model of early-onset AD). Additionally, we show that either extract prolonged the survival of a PD fly model based on transgenic expression of the human a-syn A53T mutant. Taken together, our findings suggest that the plant-derived extracts interfere with shared mechanisms of neurodegeneration in AD and PD. This notion is strengthened by evidence demonstrating that EOFI and to a greater extent EPP, while strongly inhibiting the fibrillogenesis of both AB42 and a-syn, accumulate remodelled oligomeric aggregates that are less effective at disrupting lipid membrane integrity. Our work therefore opens new avenues for developing therapeutic applications of these natural plant extracts in the treatment of amyloidogenic neurodegenerative disorders. peer-reviewed